Research output per year
Research output per year
Personal profile
Research interests
My research focuses on the personalization of high-efficacy therapies for relapsing-remitting multiple sclerosis (RRMS). By studying the pharmacokinetics and pharmacodynamics of various monoclonal antibodies, we aim to understand the significant variability in drug metabolism among MS patients. My clinical research is centered on the adjustment and personalization of these therapies, contributing to their value in terms of safety, treatment convenience, and healthcare efficiency.
Specialisation
Multiple Sclerosis, High efficacy therapies, Personalized dosing, Pharmacokinetics
Fingerprint
Dive into the research topics where Zoé van Kempen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Author response to letter to the editor
Gelissen, L. M. Y., Hogenboom, L. & van Kempen, Z. L. E., 15 Jan 2026, In: Journal of the neurological sciences. 480, 125704.Research output: Contribution to journal › Comment/Letter to the editor › Academic
Open AccessFile27 Downloads (Pure) -
Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis
Kaçar, S., van Nederpelt, D. R., Jelgerhuis, J. R., Coerver, E. M. E., Killestein, J., Sormani, M. P., Ciccarelli, O., Arnold, D. L., van Kempen, Z. L. E., Uitdehaag, B. M. J., Barkhof, F., Koch, M. W., Schoonheim, M. M., Eshaghi, A. & Strijbis, E. M. M., Jul 2026, In: Journal of neurology, neurosurgery, and psychiatry. 97, 7, p. 581-590 10 p., 337779.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile6 Downloads (Pure) -
Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis
Gelissen, L. M. Y., van den Berg, S. P. H., Toorop, A. A., Wijburg, M. T., Tallantyre, E. C., Derksen, N. I. L., Loeff, F. C., Killestein, J. & NEXT-MS study group, Jan 2026, In: Frontiers in immunology. 17, p. 1796273 1796273.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile15 Downloads (Pure) -
From authorisation to clinical practice: evolution of the use of biological medicines according to the SmPC and guidelines (2006 to 2025)
Penninx, B. M. F., Hollak, C. E. M., Tas, S. W., Timmers, L., de Visser, S. J. & van Kempen, Z. L. E., 1 Jul 2026, In: European journal of clinical pharmacology. 82, 7, 165.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Downloads (Pure) -
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab
Hogenboom, L., Schoof, L. G., Gelissen, L. M. Y., Mostert, J., van Rooij, L., Hoitsma, E., van Munster, C. E. P., van Eijk, J., Kalkers, N. F., Adriani, K. S., Vennegoor, A., Arts, I. M. P., Mensing, L., Eurelings, M., de Gans, K., Gerlach, O., Hoogervorst, E. L. J., Kloosterziel, M. E., Kragt, J. J. & Portier, R. P. & 14 others, , 1 Jul 2026, In: European journal of neurology. 33, 7, e70695.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile14 Downloads (Pure)
-
Personalized therapy in multiple sclerosis
van Kempen, Z. (Speaker)
2024Activity: Talk or presentation › Invited talk › Academic
-
MS Doelmatigheidsnetwerk (External organisation)
van Kempen, Z. (Chair)
2024 → …Activity: Membership › Membership of network › Academic
-
European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases (External organisation)
van Kempen, Z. (Member)
2023 → …Activity: Membership › Membership of network › Professional
-
Commissie Geneesmiddelen (vanuit de FMS) (External organisation)
van Kempen, Z. (Member)
2023 → …Activity: Membership › Membership of committee › Professional
-